Vetter's Chicago Facility Fully Operational - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vetter's Chicago Facility Fully Operational


Sponsored by:Vetter


Peter Soelkner
Managing Director
Vetter Pharma International GmbH


Add this Podcast feed to your media player



In 2010, Vetter brought you up to date on the company’s plans to expand its Vetter Development Service operations by opening its first manufacturing site outside of Germany. Just recently, Vetter announced that the site, located in Chicago at the Illinois Science + Technology Park in Skokie, is fully operational. Among the sites attributes, which include state-of-the-art systems and infrastructure, coupled with professional expertise, the facility is the first to use a new fully automated vial filler designed specifically for early-clinical stage, high-value biopharmaceuticals.


ONLINE RESOURCES



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here